李瑞,陳宏偉
(華中科技大學(xué)同濟(jì)醫(yī)學(xué)院附屬武漢中心醫(yī)院 婦科,湖北 武漢 430000)
婦科腫瘤患者腹腔鏡術(shù)后譫妄預(yù)測(cè)的生物標(biāo)志物分析
李瑞,陳宏偉
(華中科技大學(xué)同濟(jì)醫(yī)學(xué)院附屬武漢中心醫(yī)院 婦科,湖北 武漢 430000)
目的探討血清中性粒細(xì)胞明膠酶相關(guān)脂質(zhì)運(yùn)載蛋白(NGAL)與S-100β蛋白對(duì)婦科腫瘤患者腹腔鏡術(shù)后譫妄(POD)的預(yù)測(cè)效果。方法選取2015年3月-2016年6月該院收治的256例行腹腔鏡全麻手術(shù)的婦科腫瘤患者為研究對(duì)象,根據(jù)術(shù)后狀況分為POD組(n=31)和非POD組(n=225)。比較兩組的全麻前5 min、氣管拔管即刻、出麻醉后監(jiān)測(cè)治療室(PACU)前、術(shù)后24、48和72 h的血清NGAL、S-100β蛋白、肌酐(Scr)和胱抑素C(Cys-c)的水平。采用受試者工作曲線下面積(AUC)來評(píng)價(jià)各指標(biāo)對(duì)POD的預(yù)測(cè)效果。結(jié)果兩組全麻后的血清NGAL與S-100β的水平均明顯高于全麻前,差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。POD組的氣管拔管即刻、出PACU前、術(shù)后24 h的血清NGAL水平明顯高于非POD組,差異有統(tǒng)計(jì)學(xué)意義(P<0.05);POD組的氣管拔管即刻、出PACU前、術(shù)后24、48和72 h的血清S-100β水平明顯高于非POD組,差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。全部患者術(shù)后均未出現(xiàn)急性腎損傷(AKI),兩組不同時(shí)間點(diǎn)的血清Scr與Cys-C水平比較,差異均無統(tǒng)計(jì)學(xué)意義(P>0.05)。氣管拔管即刻、出PACU前、術(shù)后24 h的血清NGAL與S-100β的AUC分別為0.75、0.77、0.66和0.85、0.83、0.80(P<0.05)。結(jié)論血清NGAL和S-100β水平可作為婦科腫瘤患者腹腔鏡術(shù)后譫妄的早期預(yù)測(cè)指標(biāo),且后者的預(yù)測(cè)效果更加好,尤其是氣管拔管即刻與出PACU前。
譫妄;中性粒細(xì)胞明膠酶相關(guān)脂質(zhì)運(yùn)載蛋白;S-100β蛋白;預(yù)測(cè);腹腔鏡手術(shù)
譫妄,又稱為急性腦綜合征,是指一組表現(xiàn)為意識(shí)障礙、行為無章、沒有目的、注意力無法集中的臨床綜合征,術(shù)后譫妄(postoperative delirium,POD)是指術(shù)后數(shù)日內(nèi)患者出現(xiàn)譫妄狀態(tài),常起病較急,病情容易波動(dòng),好發(fā)于老年患者,此時(shí)患者的認(rèn)知功能出現(xiàn)不同程度的下降,覺醒度與感知覺均出現(xiàn)異常,由于譫妄的表現(xiàn)形式復(fù)雜多樣,故在臨床上有不少譫妄患者未能被及時(shí)發(fā)現(xiàn)與診治,從而出現(xiàn)較為嚴(yán)重的惡性后果,增加術(shù)后并發(fā)癥的發(fā)生率,嚴(yán)重者可導(dǎo)致死亡[1],故尋找POD簡便、可靠的預(yù)測(cè)指標(biāo)對(duì)其早期防治具有重要意義。目前POD的診斷主要依靠簡易精神狀態(tài)檢查量表(mini-mental state examination,MMSE)等進(jìn)行評(píng)估,缺乏一個(gè)特異的實(shí)驗(yàn)室指標(biāo),以往認(rèn)為由于炎癥反應(yīng)的激活是POD的重要發(fā)病機(jī)制,故血中白細(xì)胞介素(interleukin,IL)等炎癥因子的水平可能對(duì)POD的早期診斷有一定的預(yù)測(cè)意義,但其敏感性和特異性均較低[2]。人中性粒細(xì)胞明膠酶相關(guān)脂質(zhì)運(yùn)載蛋白(neutrophil gelatinase-associated lipocalin,NGAL)屬于lipocalin超家族,最早是從中性粒細(xì)胞內(nèi)提純出來,可共價(jià)結(jié)合于明膠酶上,因而得名。目前認(rèn)為其是一種新型的急性腎損傷(acute kidney injury,AKI)生物標(biāo)志物,與炎癥反應(yīng)、應(yīng)激等的發(fā)生有關(guān)。S-100β蛋白是一種酸性鈣結(jié)合蛋白,主要存在于神經(jīng)膠質(zhì)細(xì)胞和雪旺細(xì)胞的胞液中,因其能在飽和硫酸銨中100%溶解而得名,目前認(rèn)為其是一種中樞神經(jīng)系統(tǒng)損傷靈敏且特異的生物標(biāo)志物。本研究選取256例行腹腔鏡全麻手術(shù)的婦科腫瘤患者為研究對(duì)象,旨在探討術(shù)前血清NGAL與S-100β的水平對(duì)POD的預(yù)測(cè)效果,為臨床提供參考依據(jù)。現(xiàn)報(bào)道如下:
選取2015年3月-2016年6月我院收治的256例行腹腔鏡全麻手術(shù)的婦科腫瘤患者為研究對(duì)象。其中,年齡25~71歲,平均(45.3±13.9)歲;病因:卵巢良性腫瘤150例,子宮良性腫瘤96例,宮頸癌5例,宮頸上皮內(nèi)瘤變Ⅲ級(jí)病變5例。納入標(biāo)準(zhǔn):①所有患者的美國麻醉醫(yī)師協(xié)會(huì)(American Society of Anesthesiologists,ASA)分級(jí)為Ⅰ~Ⅱ級(jí),均成功進(jìn)行手術(shù),無術(shù)中中轉(zhuǎn)開腹及死亡者;②術(shù)前意識(shí)清楚,MMSE評(píng)分高于正常值(中學(xué)及以上人群的總分≥24分、文盲≥17分、小學(xué)≥20分);③手術(shù)前后均檢測(cè)血清NGAL與S-100β的水平,臨床資料完整可靠。排除標(biāo)準(zhǔn):①術(shù)前即有譫妄或存在意識(shí)障礙;②合并嚴(yán)重的肝、腎功能障礙不全或其他神經(jīng)系統(tǒng)疾??;③既往3個(gè)月內(nèi)有腦外科手術(shù)史;④術(shù)后72 h內(nèi)應(yīng)用鎮(zhèn)靜催眠藥或抗膽堿藥物。本研究符合醫(yī)學(xué)倫理學(xué)原則,已通過醫(yī)院倫理委員會(huì)的批準(zhǔn)。全部256例患者中有31例出現(xiàn)POD,發(fā)生率為12.1%,歸為POD組,其余225例患者歸為非POD組。兩組的年齡、ASA分級(jí)、術(shù)前合并休克、手術(shù)時(shí)間≥3 h、術(shù)中失血量≥1 L和術(shù)后放置引流管≥3根等臨床資料比較,差異無統(tǒng)計(jì)學(xué)意義(P>0.05)。見表1。
1.2.1 圍手術(shù)期的管理 所有患者均采用氣管插管靜脈全麻,進(jìn)入手術(shù)室后常規(guī)給予面罩吸氧,監(jiān)測(cè)心電圖、血氧飽和度、呼末二氧化碳分壓、心率和血壓等,Narcotrend麻醉深度監(jiān)測(cè)儀監(jiān)測(cè)其深度。麻醉誘導(dǎo)方案是:舒芬太尼0.4μg/kg、咪唑安定0.05 mg/kg、異丙酚2.50 mg/kg、維庫溴銨0.10 mg/kg,氣管插管后行機(jī)械通氣。麻醉維持方案:異丙酚2.5~4.0 mg/L、雷米芬太尼4.0~5.0μg/L靶控輸注,根據(jù)需要間斷給予維庫溴銨1.0~2.0 mg,調(diào)整輸注速度,將Narcotrend指數(shù)維持在40~60之間。手術(shù)結(jié)束后送麻醉后監(jiān)測(cè)治療室(postanesthesia care unit,PACU),常規(guī)給予胃復(fù)安10.0 mg預(yù)防嘔吐,按需給予阿托品與新斯的明行肌松的拮抗處理,清醒后拔管,后送恢復(fù)室監(jiān)護(hù)處理。
1.2.2 實(shí)驗(yàn)室檢測(cè) 分別于在全麻前5 min、氣管拔管即刻、出PACU前、術(shù)后24、48和72 h分別抽取3 ml靜脈血,5 000 r/min離心15 min后留取血清,置于-80℃低溫冰箱保存,采用南京諾爾曼生物技術(shù)有限公司提供的試劑盒檢測(cè)血清NGAL的濃度(免疫增強(qiáng)比濁法),采用德國DRG公司提供的試劑盒檢測(cè)血清S-100β的濃度(酶聯(lián)免疫吸附測(cè)定法),采用美國貝克曼AU5800全自動(dòng)生化分析儀檢測(cè)血清肌酐(serum creatinine,Scr)和胱抑素C(cystatin C,Cys-c)的濃度。
表1 兩組的臨床資料比較Table1 Comparison of clinical data between the two groups
在全麻前、出PACU前、術(shù)后24和48 h均由專業(yè)人員進(jìn)行POD的評(píng)定,采用精神紊亂評(píng)估法的標(biāo)準(zhǔn)進(jìn)行判斷,若同時(shí)符合以下第1條和第2條,且第3條或第4條中的一項(xiàng),即可診斷為譫妄:①急性發(fā)作和病程波動(dòng);②注意力不集中;③思維無序;④意識(shí)改變[3]。比較兩組的臨床資料、不同時(shí)刻的血清NGAL、S-100β、Scr和Cys-C等水平。并參考2012年KDIGO制定的AKI診斷標(biāo)準(zhǔn),若術(shù)后48 h內(nèi)Scr升高程度≥26.5μmol/L或≥術(shù)前基礎(chǔ)水平的1.5倍,則診斷為術(shù)后出現(xiàn)AKI[4]。
采用SPSS 19.0統(tǒng)計(jì)學(xué)軟件進(jìn)行數(shù)據(jù)分析,計(jì)量資料若呈正態(tài)分布,則以均數(shù)±標(biāo)準(zhǔn)差(±s)表示,兩組比較用t檢驗(yàn)。計(jì)數(shù)資料以例數(shù)和百分比(率)表示,采用χ2檢驗(yàn)。繪制血清NGAL、S-100β水平對(duì)患者出現(xiàn)POD的預(yù)測(cè)價(jià)值的受試者工作曲線(receiver operating characteristic,ROC),根據(jù)曲線下面積(area under curve,AUC)評(píng)價(jià)各指標(biāo)的診斷價(jià)值,0.50~0.70提示價(jià)值較低,0.70~0.90提示價(jià)值中等,>0.90提示價(jià)值較高。以P<0.05為差異有統(tǒng)計(jì)學(xué)意義。
兩組全麻后的血清NGAL與S-100β的水平均明顯高于全麻前,差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。兩組比較,POD組的氣管拔管即刻、出PACU前、術(shù)后24 h的血清NGAL水平明顯高于非POD組,差異有統(tǒng)計(jì)學(xué)意義(P<0.05);POD組的氣管拔管即刻、出PACU前、術(shù)后24、48和72 h的血清S-100β水平明顯高于非POD組,差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。見表2。
全部患者術(shù)后均未出現(xiàn)AKI。組內(nèi)比較,兩組患者的術(shù)后24 h內(nèi)的血Scr均明顯高于全麻前5 min(P<0.05),之后逐漸降低,手術(shù)前后的血Cys-C無顯著變化。組間比較,兩組的不同時(shí)點(diǎn)血清Scr與Cys-C水平比較,差異均無統(tǒng)計(jì)學(xué)意義(P>0.05)。見表3。
預(yù)測(cè)POD方面,氣管拔管即刻、出PACU前和術(shù)后24 h的血清NGAL與S-100β的AUC分別為0.75、0.77、0.66和 0.85、0.83、0.80,與 AUC=0.50相比,差異均有統(tǒng)計(jì)學(xué)意義(P<0.05)。見表4。各ROC分析曲線參見圖1~3。由圖可知,無論是哪個(gè)時(shí)刻,S-100β對(duì)POD的預(yù)測(cè)效果優(yōu)于同期的NGAL,且氣管拔管即刻的血清S-100β的預(yù)測(cè)價(jià)值最高。
表2 兩組不同時(shí)間點(diǎn)的血清NGAL與S-100β的水平比較 (±s)Table 2 Comparison of serum NGAL and S-100β levels between the two groups at different time points (±s)
表2 兩組不同時(shí)間點(diǎn)的血清NGAL與S-100β的水平比較 (±s)Table 2 Comparison of serum NGAL and S-100β levels between the two groups at different time points (±s)
注:?與組內(nèi)全麻前5 min的水平比較,P <0.05
組別 全麻前5 min 氣管拔管即刻 出PACU前 術(shù)后24 h 術(shù)后48 h 術(shù)后72 h血 NGAL/(ng/ml)POD組(n =31) 42.90±14.70 115.40±47.20? 123.80±50.10? 139.70±31.60? 101.60±22.70? 59.70±9.30?非POD組(n =225) 39.70±18.20 98.70±35.70? 105.10±37.30? 126.90±32.70? 92.90±24.00? 63.20±15.50?t值 0.94 2.34 2.50 2.05 1.90 1.23 P值 0.350 0.020 0.013 0.041 0.058 0.221血 S-100β/(pg/ml)POD組(n =31) 62.60±12.30 123.70±28.90? 142.60±32.30? 150.70±45.60? 138.90±38.70? 123.80±33.30?非POD組(n =225) 58.90±12.80 72.70±15.40? 95.70±18.70? 101.80±30.30? 92.60±27.00? 85.70±25.40?t值 1.52 15.17 11.78 7.86 8.44 7.52 P值 0.131 0.000 0.000 0.000 0.000 0.000
表3 兩組不同時(shí)間點(diǎn)的血Scr與Cys-C水平比較 (±s)Table 3 Comparison of serum Scr and Cys-C levels between the two groups at different time points (±s)
表3 兩組不同時(shí)間點(diǎn)的血Scr與Cys-C水平比較 (±s)Table 3 Comparison of serum Scr and Cys-C levels between the two groups at different time points (±s)
注:?與組內(nèi)全麻前5 min的水平比較,P <0.05
組別 全麻前5 min 氣管拔管即刻 出PACU前 術(shù)后24 h 術(shù)后48 h 術(shù)后72 h血 Scr/(μg/L)POD組(n =31) 63.60±20.50 65.70±22.30 71.70±25.90 77.20±19.70? 68.20±18.80 65.90±15.50非POD組(n =225) 59.10±25.70 62.10±26.60 66.80±30.50? 69.80±21.10? 65.60±23.00? 62.70±20.80 t值 0.93 0.72 0.85 1.85 0.60 0.83 P值 0.351 0.473 0.395 0.066 0.548 0.410血 Cys-C/(μmol/L)POD 組(n =31) 1.02±0.25 1.03±0.29 0.97±0.31 0.95±0.33 0.89±0.28 0.91±0.23非 POD 組(n =225) 0.98±0.27 1.02±0.33 1.01±0.35 1.03±0.32 0.95±0.34 0.96±0.29 t值 0.78 0.16 0.60 1.30 1.10 0.92 P值 0.436 0.873 0.546 0.195 0.274 0.358
表4 不同時(shí)間點(diǎn)的血清NGAL與S-100β的水平對(duì)發(fā)生POD的預(yù)測(cè)價(jià)值比較Table 4 Comparison of predictive value of serum NGAL and S-100β levels on POD at different time points
圖1 氣管拔管即刻的血清NGAL與S-100β的水平對(duì)發(fā)生POD的預(yù)測(cè)ROC曲線Fig.1 ROC curve of serum NGAL and S-100β levels on POD at immediate tracheal extubation
圖2 出PACU前的血清NGAL與S-100β的水平對(duì)發(fā)生POD的預(yù)測(cè)ROC曲線Fig.2 ROC curve of serum NGAL and S-100β levels on POD before PACU
圖3 術(shù)后24 h的血清NGAL與S-100β的水平對(duì)發(fā)生POD的預(yù)測(cè)ROC曲線Fig.3 ROC curve of serum NGAL and S-100β levels on POD at postoperative 24 h
譫妄的特征是意識(shí)水平、認(rèn)知功能和情感等功能出現(xiàn)波動(dòng)性紊亂,POD是手術(shù)后的常見急性腦病綜合征,能顯著延長住院天數(shù),增加并發(fā)癥的發(fā)生風(fēng)險(xiǎn)和死亡率,加重了家庭和社會(huì)的負(fù)擔(dān)。本研究選取256例行腹腔鏡全麻手術(shù)的婦科腫瘤患者為研究對(duì)象,發(fā)現(xiàn)POD的發(fā)生率達(dá)到12.1%,POD與非POD患者的年齡、ASA分級(jí)、病因、術(shù)前合并休克、手術(shù)時(shí)間≥3 h、術(shù)中失血量≥1 L和術(shù)后放置引流管≥3根等臨床資料比較,差異無統(tǒng)計(jì)學(xué)意義(P>0.05),提示常見的圍手術(shù)期資料可能難以準(zhǔn)確預(yù)測(cè)POD的發(fā)生風(fēng)險(xiǎn),有必要尋找一個(gè)可早期預(yù)測(cè)POD的簡便、可靠的實(shí)驗(yàn)室指標(biāo),來達(dá)到早期診治的目的。
NGAL是中性粒細(xì)胞激活后合成并釋放的蛋白質(zhì)之一,在正常情況下,機(jī)體內(nèi)NGAL的表達(dá)水平極低,但在炎癥反應(yīng)或應(yīng)激條件下,腎臟、肺部和結(jié)腸等多個(gè)組織細(xì)胞均可合成NGAL,且其表達(dá)水平與機(jī)體代謝關(guān)系密切,故可作為全身炎癥反應(yīng)的標(biāo)志物[5-6],尤其是在AKI患者中,多個(gè)研究[7-8]表明血液和尿液NGAL對(duì)AKI的發(fā)生具有較好的預(yù)測(cè)效果。黃鵬等[9]研究表明尿液中NGAL對(duì)重癥顱腦外傷患者AKI的早期診斷價(jià)值高于Scr,可作為早期診斷AKI的標(biāo)志物。值得注意的是,外科手術(shù)本身是一個(gè)應(yīng)激因素,術(shù)后患者處于不同程度的炎癥狀態(tài),而POD與炎癥反應(yīng)關(guān)系密切[10],故圍手術(shù)期的NGAL水平與POD之間可能有關(guān)。部紹晉等[11]研究表明老年單側(cè)全髖、膝關(guān)節(jié)置換術(shù)患者氣管插管時(shí)、術(shù)后24 h的血漿/尿液NGAL對(duì)POD的早期診斷和預(yù)測(cè)有一定價(jià)值。本研究選取行腹腔鏡全麻手術(shù)的婦科腫瘤患者為研究對(duì)象,結(jié)果表明全部患者行麻醉誘導(dǎo)后的血清NGAL的水平明顯升高,至少持續(xù)到術(shù)后72 h,且POD患者的氣管拔管即刻、出PACU前、術(shù)后24 h的血清NGAL水平明顯高于非POD組(P<0.05),ROC曲線分析結(jié)果表明氣管拔管前、出PACU前、術(shù)后24 h的血清NGAL水平對(duì)預(yù)測(cè)POD的AUC分別為0.75、0.77、0.66(P<0.05),提示這3個(gè)時(shí)間點(diǎn)的血清NGAL水平具有早期預(yù)測(cè)價(jià)值,尤其是氣管拔管前、出PACU前,其AUC均超過0.70,敏感性和特異性均在80.0%左右,具有中等的早期診斷價(jià)值,且全部患者術(shù)后均未出現(xiàn)AKI,兩組的血Scr與Cys-C水平比較無顯著差異,提示血清NGAL水平除了早期診斷AKI外,對(duì)手術(shù)患者的POD同樣具有早期預(yù)測(cè)價(jià)值。
S-100β蛋白主要聚集在大腦星形膠質(zhì)細(xì)胞和雪旺細(xì)胞內(nèi),具有多種細(xì)胞調(diào)節(jié)功能,在正常情況下,由于該蛋白的分子量較大,不能透過血腦屏障,故血中難以檢測(cè)到S-100β,但當(dāng)出現(xiàn)中樞神經(jīng)系統(tǒng)細(xì)胞受損或血-腦屏障破壞時(shí),大量S-100β蛋白進(jìn)入血循環(huán),導(dǎo)致血S-100β的水平明顯增加,故血S-100β蛋白水平是顱腦損傷和/或血-腦屏障完整性降低的生物標(biāo)記物之一[3]。手術(shù)創(chuàng)傷可促進(jìn)如IL、腫瘤壞死因子(tumor necrosis factor,TNF)和干擾素等促炎細(xì)胞因子的釋放,從而引起彌散性微循環(huán)功能障礙,出現(xiàn)血管壁上皮細(xì)胞腫脹、白細(xì)胞的黏附、毛細(xì)血管狹窄、組織細(xì)胞灌注減少,導(dǎo)致腦細(xì)胞水腫,血-腦屏障通透性增加,甚至促進(jìn)腦細(xì)胞凋亡,最終促使S-100β蛋白外滲入血,出現(xiàn)血S-100β蛋白水平升高。VAN MUNSTER等[3]研究表明老年P(guān)OD患者的血S-100β蛋白水平變化與白細(xì)胞介素-6(interleukin-6,IL-6)和白細(xì)胞介素 -8(interleukin-8,IL-8)濃度變化相關(guān),其認(rèn)為神經(jīng)系統(tǒng)炎性反應(yīng)與腦功能紊亂有關(guān),可能是POD的病理生理途徑之一。方開云等[12]根據(jù)年齡將在全麻下行腹部手術(shù)的400例患者分為青年組(Ⅰ組,18~44歲)、中年組(Ⅱ組,45~59歲)、老年組(Ⅲ組,60~74歲)與高齡組(Ⅳ組,≥75歲),結(jié)果表明Ⅰ組~Ⅳ組的血清S-100β蛋白濃度對(duì)判斷POD的ROC曲線的AUC分別為0.33、0.35、0.62和0.92,靈敏度與特異度分別為50.0%、50.0%、56.0%、88.0% 與 29.0%、22.0%、46.0%、86.0%,提示血清S-100β蛋白濃度升高可預(yù)測(cè)高齡患者POD的發(fā)生。楊云麗等[13]研究表明行髖關(guān)節(jié)置換術(shù)的高齡患者術(shù)后若出現(xiàn)譫妄,其血S-100β蛋白濃度明顯升高,可作為早期診斷POD的指標(biāo)。本研究結(jié)果表明,對(duì)于行腹腔鏡全麻手術(shù)的婦科腫瘤患者而言,POD組的氣管拔管即刻、出PACU前、術(shù)后24、48和72 h的血清S-100β水平明顯高于非POD組(P<0.05),氣管拔管即刻、出PACU前和術(shù)后24 h的AUC分別為 0.85、0.83和0.80(P<0.05),提示血清S-100β水平對(duì)POD具有早期診斷價(jià)值,尤其是氣管拔管即刻,且同時(shí)刻的血清S-100β水平的預(yù)測(cè)價(jià)值高于NGAL。
綜上所述,血清NGAL和S-100β水平可作為婦科腫瘤患者腹腔鏡術(shù)后譫妄的早期預(yù)測(cè)指標(biāo),且后者的預(yù)測(cè)效果更加好,尤其是氣管拔管即刻與出PACU前。
[1]CHAPUT A J, BRYSON G L. Postoperative delirium: risk factors and management:continuing professional development[J]. Can J Anaesth, 2012, 59(3): 304-320.
[2]RITTER C, TOMASI C D, DAL-PIZZOL F, et al. Inflammation biomarkers and delirium in critically ill patients[J]. Crit Care,2014, 18(3): R106.
[3]VAN MUNSTER B C, KORSE C M, DE ROOIJ S E, et al. Markers of cerebral damage during delirium in elderly patients with hip fracture[J]. BMC Neurology, 2009, 9: 21.
[4]STEVENS P E, LEVIN A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline[J]. Ann Intern Med, 2013, 158(11):825-830.
[5]CHAKRABORTY S, KAUR S, GUHA S, et al. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in in flammation and cancer[J]. Biochim Biophys Acta, 2012, 1826(1):129-169.
[6]SERRA R, GRANDE R, MONTEMURRO R, et al. The role of matrix metalloproteinases and neutrophil gelatinase-associated lipocalin in central and peripheral arterial aneurysms[J]. Surgery,2015, 157(1): 155-162.
[7]MACDONALD S, ARENDTS G, NAGREE Y, et al. Neutrophil Gelatinase-Associated Lipocalin (NGAL) predicts renal injury in acute decompensated cardiac failure: a prospective observational study[J]. BMC Cardiovasc Disord, 2012, 12: 8.
[8]BHAVSAR N A, K?TTGEN A, CORESH J, et al. Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM-1) as predictors of incident CKD stage 3: the Atherosclerosis Risk in Communities (ARIC) Study[J]. Am J Kidney Dis, 2012, 60(2):233-240.
[9]黃鵬, 林栩, 王潔, 等. uNGAL對(duì)重癥顱腦創(chuàng)傷患者發(fā)生急性腎損傷的早期診斷價(jià)值研究[J].重慶醫(yī)學(xué), 2014, 43(31): 4203-4205.
[9]HUANG P, LIN X, WANG J, et al. Early diagnosis value of urinary NGAL in acute kidney injury in patients with severe traumatic brain injury[J]. Chongqing Medicine, 2014, 43(31): 4203-4205.Chinese
[10]CEREJEIRA J, NOGUEIRA V, LUíS P, et al. The cholinergic system and inflammation: common pathways in delirium pathophysiology[J]. J Am Geriatr Soc, 2012, 60(4): 669-675.
[11]部紹晉. 右美托嘧啶對(duì)老年患者髖、膝關(guān)節(jié)置換術(shù)術(shù)后譫妄及圍術(shù)期NGAL影響的研究[D]. 重慶醫(yī)科大學(xué), 2015.
[11]BU S J. Effects of dexmedetomidine on postoperative delirium and perioperative ngal levels in old patients with hip or knee arthroplasty[D]. Medical University of Chongqing, 2015. Chinese
[12]方開云, 朱焱, 馮亞平, 等. 血清S-100β蛋白和NSE水平預(yù)測(cè)不同年齡患者術(shù)后譫妄的準(zhǔn)確性[J]. 中華麻醉學(xué)雜志,2012, 32(1): 27-30.
[12]FANG K Y, ZHU Y, FENG Y P, et al. Accuracy of serum S-100β protein and neuron specific enolase level in prediction of postoperative delirium in different age patients[J]. Chinese Journal of Anesthesiology, 2012, 32(1): 27-30. Chinese
[13]楊云麗, 麻偉青, 張承華, 等. 高齡髖關(guān)節(jié)置換術(shù)后譫妄患者血清S-100β蛋白和NSE濃度的變化及臨床意義[J]. 昆明醫(yī)科大學(xué)學(xué)報(bào), 2014, 35(4): 61-64.
[13]YANG Y L, MA W Q, ZHANG C H, et al. Change and significience of plasma S-100β protein and NSE in elderly patients with delirium after hip joint replacement[J]. Journal of Kunming Medical University, 2014, 35(4): 61-64. Chinese
Biomarker analysis of prediction of delirium after laparoscopic surgery in gynecologic oncology
Rui Li, Hong-wei Chen
(Department of Gynecology, Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, China)
ObjectiveTo investigate the prognostic value of serum neutrophil gelatinase associated protein lipocalin (NGAL) and S-100β protein level on postoperative delirium (POD) in patient underwent gynecological laparoscopic tumor resection.Methods256 patients underwent gynecological laparoscopic tumor resection from March 2015 to June 2016 were enrolled the study and divided into POD group (n= 31) and non-POD group(n= 225). Serum levels of NGAL, S-100β protein, creatinine (Scr) and cystatin C (Cys-c) were compared between the two groups at 5 min before anesthesia induction, immediately after extubation, during their stay in post anesthesia care unit (PACU) and at 24, 48, 72 h after operation. The area under receiver-operating characteristic curve (AUC)was performed to evaluate prognostic value of each index in POD.ResultsSerum levels of NGAL and S-100β after anesthesia in the two groups were all significantly higher than those before anesthesia (P< 0.05). Serum levels of NGAL in POD group immediately after extubation, during their stay in PACU and at 24 h after operation were signi ficantly higher than those in non-POD group (P< 0.05). Serum levels of S-100β protein in POD group immediately after extubation, durng their stay in PACU and at 24, 48, 72 h after operation were signi ficantly higherthan those in non-POD group (P< 0.05). There was no acute renal injury in all patients. There were no signi ficant difference in serum levels of Scr and Cys-C between two groups at every time points (P> 0.05). The AUC of serum NGAL and S-100 protein immediately after extubation, durng their stay in PACU and at 24h after operation were 0.75, 0.77, 0.66 and 0.85, 0.83, 0.80 respectively (P< 0.05).ConclusionsSerum NGAL and S-100β protein levels could be used as predictors of POD in patients undergoing gynecological laparoscopic tumor resection, and prediction effect of the latter was better, especially immediately after extubation and durng their stay in PACU.
delirium; neutrophil gelatinase associated protein lipocalin; S-100β protein; prediction;laparoscopic surgery
R749
A
10.3969/j.issn.1007-1989.2017.09.005
1007-1989(2017)09-0024-07
2017-02-14
(吳靜 編輯)